Subscribe To
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Replimune presents updated interim results from the artacus clinical trial of rp1 monotherapy in solid organ and hematopoietic cell transplant recipients with skin cancers during oral presentation at
RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients WOBURN, Mass., Nov. 03, 2...
November 3, 2023, 11:30 pm
Aligos therapeutics to host kol event to discuss alg-000184 phase 1, aasld late breaker data
November 16 Event to feature KOL perspective on Emerging HBV Therapies SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeu...
November 3, 2023, 8:30 pm
Turnstone biologics presents preclinical data highlighting potential for selected tumor-infiltrating lymphocyte (til) therapy in solid tumors at the 2023 society for immunotherapy of cancer (sitc) ann
Presentations showcase Turnstone’s novel Selected TIL programs which are designed to selectively expa...
November 3, 2023, 10:00 am
Ncv: troubled history but novel concept
Virtus Convertible & Income Fund offers a high level of current income with a yield of 13.97%. The NCV closed-end fund heavily invests in convertible ...
November 2, 2023, 11:53 am
Ocugen to host conference call on thursday, november 9 at 8:30 a.m. et to discuss business updates and third quarter 2023 financial results
MALVERN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, ...
November 2, 2023, 11:30 am
Vincerx pharma to present three posters at ash 2023 in december
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this ...
November 2, 2023, 9:10 am
Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...
November 2, 2023, 9:09 am
Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato
BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...
November 2, 2023, 9:09 am
Molecular partners to present initial data from ongoing phase 1/2a trial of mp0533 for patients with relapsed/refractory aml and aml/mds at the 65th ash annual meeting and exposition
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...
November 2, 2023, 2:00 am
Corvus pharmaceuticals announces publication of preclinical data demonstrating potential of itk inhibition with soquelitinib as a novel approach to t cell-mediated inflammatory and immune diseases
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th...
November 1, 2023, 11:31 pm
Hillevax to present at upcoming investor conferences
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci...
November 1, 2023, 4:48 pm
Siren biotechnology awarded $4m in grant funding from the california institute for regenerative medicine (cirm)
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Siren Biotechnology, a gene therapy company pioneering Universal AAV Immuno-Gene Therapies for Cance...
November 1, 2023, 4:46 pm
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...
November 1, 2023, 11:30 am
Zymeworks announces participation in upcoming investor conferences
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,...
November 1, 2023, 8:30 am
Aptevo to present at bio-europe conference
SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing
November 1, 2023, 7:45 am
Apnimed announces launch of joint venture with shionogi to develop novel pharmacologic therapies for obstructive sleep apnea and other sleep disorders
$150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for...
November 1, 2023, 12:00 am
Lirum therapeutics presents positive data on lx-101, a novel clinical-stage targeted therapy, demonstrating potent preclinical activity against pediatric sarcomas
New York, NY, Oct. 31, 2023 (GLOBE NEWSWIRE) — Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focuse...
October 31, 2023, 5:27 pm